Compare PESI & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | STRO |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.3M | 332.8M |
| IPO Year | 1996 | 2018 |
| Metric | PESI | STRO |
|---|---|---|
| Price | $15.60 | $16.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 261.8K | ★ 288.8K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $642,000.00 | ★ $38,419,000.00 |
| Revenue This Year | $34.62 | N/A |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.58 | $0.72 |
| 52 Week High | $21.32 | $43.85 |
| Indicator | PESI | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 30.44 |
| Support Level | $14.18 | $14.81 |
| Resistance Level | $16.25 | $17.33 |
| Average True Range (ATR) | 0.82 | 1.05 |
| MACD | -0.38 | 0.09 |
| Stochastic Oscillator | 13.32 | 22.32 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.